Eli Lilly and Co (NYSE:LLY) – Analysts at Jefferies Group decreased their FY2021 EPS estimates for Eli Lilly and in a research note issued to investors on Tuesday. Jefferies Group analyst J. Holford now expects that the company will post earnings of $6.75 per share for the year, down from their previous forecast of $6.77. Jefferies Group has a “Buy” rating and a $100.00 price objective on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2022 earnings at $7.42 EPS.
Several other equities analysts have also weighed in on the stock. Goldman Sachs Group lowered shares of Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their target price for the company from $86.98 to $95.00 in a report on Tuesday. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and lifted their target price for the company from $85.52 to $115.00 in a report on Friday, January 5th. Credit Suisse Group restated a “hold” rating on shares of Eli Lilly and in a report on Wednesday, December 13th. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 12th. Finally, Morgan Stanley lifted their target price on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a report on Tuesday, November 21st. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $92.75.
Eli Lilly and (NYSE:LLY) traded down $0.39 during trading hours on Wednesday, hitting $85.82. 4,445,813 shares of the company traded hands, compared to its average volume of 3,320,000. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The firm has a market cap of $94,500.00, a price-to-earnings ratio of 40.87, a price-to-earnings-growth ratio of 1.60 and a beta of 0.35. Eli Lilly and has a 1-year low of $74.00 and a 1-year high of $89.09.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. Eli Lilly and’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the business earned $0.88 EPS.
Institutional investors have recently added to or reduced their stakes in the stock. Private Trust Co. NA increased its position in shares of Eli Lilly and by 9.4% in the 2nd quarter. Private Trust Co. NA now owns 8,518 shares of the company’s stock worth $700,000 after purchasing an additional 731 shares during the last quarter. New England Research & Management Inc. bought a new stake in shares of Eli Lilly and in the 2nd quarter worth about $354,000. Appleton Partners Inc. MA increased its position in shares of Eli Lilly and by 4.9% in the 2nd quarter. Appleton Partners Inc. MA now owns 7,001 shares of the company’s stock worth $576,000 after purchasing an additional 325 shares during the last quarter. Bank of Montreal Can increased its position in shares of Eli Lilly and by 66.9% in the 2nd quarter. Bank of Montreal Can now owns 1,508,937 shares of the company’s stock worth $124,186,000 after purchasing an additional 604,577 shares during the last quarter. Finally, First Financial Bank Trust Division increased its position in shares of Eli Lilly and by 11.3% in the 2nd quarter. First Financial Bank Trust Division now owns 5,705 shares of the company’s stock worth $469,000 after purchasing an additional 578 shares during the last quarter. 76.35% of the stock is currently owned by hedge funds and other institutional investors.
In related news, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the sale, the senior vice president now owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the sale, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold a total of 251,088 shares of company stock worth $22,041,236 in the last ninety days. 0.20% of the stock is currently owned by insiders.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 annualized dividend and a yield of 2.62%. Eli Lilly and’s payout ratio is 99.05%.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.